Leaving the study early: insufficient response ‐ When compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
4 findings from 1 review
Show 1 more finding
Adverse effects: 6. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus low dose (greater than or equal to 2‐<4 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus low dose (greater than or… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐lower dose (greater than or equal to 4‐<6 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in adverse effects: EPS: unspecified ‐ Versus standard‐lower dose… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mean VAS pain per day · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) showed no clear difference in mean VAS pain per day compared with placebo; GRADE not reported.
1 finding from 1 review
Total number of new ulcers over 90 days · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) led to lower total number of new ulcers over 90 days compared with placebo; GRADE not reported.
1 finding from 1 review
Number of ulcers at end of 90-day treatment · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) showed no clear difference in number of ulcers at end of 90-day treatment compared with placebo; GRADE not reported.
1 finding from 1 review
Average number of new lesions per week · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Subantimicrobial dose doxycycline (20 mg twice daily for 90 days) led to lower number of new lesions per day compared with placebo; GRADE not reported.
1 finding from 1 review
Time to resolution of first ulcer (days) · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Montelukast (leukotriene receptor antagonist; 10 mg daily for 1… led to lower time to resolution of first ulcer (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Swelling (mean) · Adults with a symptomatic necrotic tooth or localised acute apical abscess (no signs of spreading infection or systemic involvement)
Postoperative systemic antibiotics… showed no clear difference in swelling at 48 hours compared with matched placebo, partial or total chemo-mechanical debridement and…; GRADE not reported.
4 findings from 1 review
SMD 0.04 [-0.47, 0.55]
2 studies · 61 participants
GRADE not reported
SMD 0.27 [-0.23, 0.78]
2 studies · 62 participants
Very low
SMD 0.02 [-0.49, 0.52]
2 studies · 61 participants
Very low
Show 1 more finding
Percussion pain at 7 days · Adults with a symptomatic necrotic tooth or localised acute apical abscess (no signs of spreading infection or systemic involvement)
Postoperative systemic antibiotics… showed no clear difference in percussion pain at 7 days compared with matched placebo, partial or total chemo-mechanical debridement and…; GRADE not reported.
1 finding from 1 review
Pain at 7 days · Adults with a symptomatic necrotic tooth or localised acute apical abscess (no signs of spreading infection or systemic involvement)
It is very uncertain whether postoperative systemic antibiotics… changes pain at 7 days compared with matched placebo, partial or total chemo-mechanical debridement and… (very low certainty).
1 finding from 1 review
BPD or death by it prior to 37 weeks' PMA (outcomes collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome
Inositol supplementation IV initially followed by enteral… showed no clear difference in BPD or death by it prior to 37 weeks' PMA (outcomes collected… compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality (outcome collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome
Inositol supplementation IV initially followed by enteral… showed no clear difference in all‐cause mortality (outcome collected through first event: death,… compared with placebo (moderate certainty).
1 finding from 1 review
Adjusted drowning mortality risk · 1‐ to 5‐year‐old children in LMICs
1 finding from 1 review